相关实验视频

Updated: Jun 17, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

准宿主硫基尿素受体2可以降低Helicobacter pylori相关胃炎的严重程度

Sohinee Sarkar^1,2, Ghazal Alipour Talesh^1,2, Trevelyan R Menheniott^1,2

¹Infection and Immunity, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia.

Gastro hep advances

|August 12, 2024

概括

向SUR2 (ABCC9) 通道子单元可以减少Helicobacter pylori诱导的胃炎的严重程度. 这项研究揭示了SUR2作为H. pylori病变的新型宿主因子,提供了一条新的治疗途径.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

杆菌感染会在很大一部分人中引起慢性胃炎和胃癌.
主体通道调节子单元SUR2 (ABCC9) 作为潜在的治疗标被研究.
了解宿主因素对于开发针对H. pylori相关疾病的新策略至关重要.

研究的目的:

为了研究SUR2 (ABCC9) 在H. pylori病变发生中的作用.
评估针对 H. pylori 相关性胃炎的 SUR2 的治疗潜力.
探索SUR2调节宿主对H. pylori的反应的机制.

主要方法:

定量PCR分析了人类和小鼠胃活检中的ABCC9基因表达.
感染H. pylori的小鼠接受了SUR2通道激动剂 (pinacidil,nicorandil) 的治疗.
用组织学,免疫组织化学和ELISA分析了胃和脏组织;在体外研究中使用了巨细胞,上皮细胞和细胞.

主要成果:

在H. pylori感染的人类和小鼠胃中,ABCC9的表达被下调.
用皮纳西迪尔或尼科兰迪尔治疗显著降低了感染小鼠胃炎的严重程度.
在体外,尼科兰迪尔增加了细胞内K+,防止了H. pylori介导的Ca2+流入和胃上皮细胞的炎症.

结论:

SUR2是一种新型宿主因子,影响着Helicobacter的病变发生.
药理学调节SUR2是一个潜在的策略,以减轻H. pylori相关的胃炎的严重程度.
向SUR2提供了一种独立于细菌根除的治疗方法.

关键词:

胃炎是一种胃炎.在Helicobacter Pylori的研究中,通道是一种通道.在SUR2中使用.它具有治疗性的作用.

更多相关视频

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...